Skip to main content
. 2016 Dec 19;8(2):2053–2068. doi: 10.18632/oncotarget.14026

Figure 6. Autologously reconstituted HNSCC tumor system can be used to study human myeloid derived suppressor cells as well as novel immunomodulatory agents.

Figure 6

a. Splenocytes from autologously reconstituted human tumor bearing mice were harvested, and CD11b+CD14+DRlow (CD14) and CD11b+CD15+DRlow (CD15) cells were sorted to homogeneity to ensure monocytic and granulocytic histology (data not shown)[21]. Human CD3+ cells were co-cultured with CD11b+CD14+HLA-DRlow and CD11b+CD15+HLA-DRlow cells in complete RPMI media and stimulated (Sti) with PMA/Ionomycin. CD3+IFNγ+ cells were quantitated with flow cytometry as the measurement of T-cell suppression when mixed with MDSC. b. Palpable tumors of equivalent size in both groups were treated intratumorally with either PBS control or ML-RR-CDA at 20µg per injection and the tumor growth was followed. Experiment repeated twice with 4-5 mice per group. At the completion of experiment, the tumor was harvested and stained with human CD8, IFNγ, and DAPI counterstain (right panels). The bar scale is 100µ.